Swiss pharmaceutical company Nycomed enters Turkish market


Bugun - Swiss pharmaceutical company Nycomed has entered the Turkish market with the aim of achieving a USD 25 million annual turnover. Guido Oelkers, Nycomed’s Executive Vice President of Commercial Operations, said their investments are focused on emerging countries such as Mexico, China, India and Turkey. “Turkey is a rapidly growing market with an advanced infrastructure. Turkey will be a key market for Nycomed with its growing importance”, said Oelkers, adding that the company is aiming to rank among the top 20 pharmaceutical companies by 2014.

Turkey; pharmaceutical industry; Swiss company; pharmaceutical market; healthcare sector; Nycomed; Guido Oelkers